RxDoctor Payments DataLook up a doctor →

Martin Hopp, MD

Otolaryngology · Los Angeles, CANPI 1336284561

Payments from drug & device makers

$320,957in general payments, 2019–2025

Across 239 payments — averaging $1342.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$298K
  • AstraZeneca$17K
  • Aerin Medical Inc.$791
  • GSK$665
  • Inspire Medical Systems, Inc.$589
  • Sanofi$509
  • plus $3K from 16 others

What the payments were for

  • Consulting fees$1002%
  • Speaking & faculty fees$4007%
  • Food & beverage$5,27391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$320,957 in reported general payments places this provider in the 95th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California

Medicare billing

Part B allowed, 2024
$1,377,765
Medicare patients
887
Services billed
6,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$8,851
MyrbetriqMirabegron20$8,844
GemtesaVibegron12$5,874
Azelastine Hcl102$2,745
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort33$1,543
Ipratropium Bromide65$1,381
Fluocinolone Acetonide Oil16$873
WaterWater For Irrigation,sterile13$451
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav31$321
Dexamethasone13$290
Omeprazole13$241
Montelukast Sodium14$203
Fluticasone Propionate12$157
CefuroximeCefuroxime Axetil13$153
Azithromycin20$63

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →